Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Adaptimmune Therapeutics (ADAP) Stock Price

News headlines about Adaptimmune Therapeutics (NASDAQ:ADAP) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adaptimmune Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.0726703814678 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

How to Become a New Pot Stock Millionaire

A number of brokerages have weighed in on ADAP. BidaskClub upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 23rd. Leerink Swann reiterated an “outperform” rating on shares of Adaptimmune Therapeutics in a research report on Thursday, March 15th. ValuEngine upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Finally, Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $11.58.

Adaptimmune Therapeutics stock opened at $10.42 on Friday. Adaptimmune Therapeutics has a 1-year low of $4.28 and a 1-year high of $13.41. The company has a market capitalization of $1,052.14, a PE ratio of -13.03 and a beta of 1.19.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04). Adaptimmune Therapeutics had a negative net margin of 185.39% and a negative return on equity of 32.26%. The firm had revenue of $4.27 million during the quarter, compared to analysts’ expectations of $9.38 million. sell-side analysts forecast that Adaptimmune Therapeutics will post -0.82 earnings per share for the current year.

In other news, major shareholder Ravi Viswanathan purchased 104,844 shares of the company’s stock in a transaction dated Wednesday, March 21st. The stock was acquired at an average price of $1.81 per share, with a total value of $189,767.64. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David M. Mott purchased 571,164 shares of the company’s stock in a transaction dated Monday, March 26th. The stock was purchased at an average cost of $1.90 per share, with a total value of $1,085,211.60. The disclosure for this purchase can be found here. In the last three months, insiders bought 9,385,254 shares of company stock valued at $17,966,655. Corporate insiders own 24.45% of the company’s stock.

WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Adaptimmune Therapeutics (ADAP) Stock Price” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-adaptimmune-therapeutics-adap-stock-price.html.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.

Insider Buying and Selling by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply